Agenda for 19 October Transparency Commission meeting

12 October 2016 - HAS has published the agenda for the next scheduled Transparency Commission meeting. ...

Read more →

Idelvion now registered in Australia

27 September 2016 - CSL Behring's Idelvion is now approved by the TGA. ...

Read more →

Agenda for 21 September 2016 TC meeting

19 September 2016 - The Transparency Commission will consider the reimbursement of a number of new medicines and blood products. ...

Read more →

TGA approves new indication for Alprolix

15 September 2016 - The TGA has approved a new use for Biogen's Alprolix. ...

Read more →

Shire announces U.S. FDA approval of Cuvitru [immune globulin (human), 20% solution for subcutaneous injection] treatment for primary immunodeficiency

14 September 2016 - Approval follows positive data from clinical studies on efficacy and tolerability, as well as infusion time and ...

Read more →

Shire announces FDA approval of Adynovate with Baxject III reconstitution system

1 August 2016 - New system reduces number of steps in the treatment process for haemophilia A patients on Adynovate [antihemophilic ...

Read more →

ADMA Biologics receives complete response letter from FDA for pending biologics license application

29 Jul 2016 - ADMA Biologics announced that the U.S. FDA has issued a complete response letter to the company’s biologics ...

Read more →

Agenda for the 20 July 2016 TC meeting

15 July 2016 - The Transparency Commission will consider the reimbursement of new medicines and blood products. ...

Read more →

Agenda for the 6 July 2016 TC meeting

30 June 2016 - The Transparency Commission will consider the reimbursement of new medicines and blood products. ...

Read more →

TGA publishes AusPAR for simoctocog alfa rhu (Nuwiq)

17 June 2016 - The TGA has published an AusPAR for Octapharma's Nuwiq (simoctocog alfa). ...

Read more →

Shire and Kamada announce FDA approval of expanded label for self-infusion of Glassia for the treatment of emphysema due to severe AAT deficiency

15 June 2016 - Glassia is the only FDA approved alfa-1 antitrypsin (human) augmentation treatment that patients can self-infuse at home. ...

Read more →

Agenda for the 8 June 2016 TC meeting

1 June 2016 - The Transparency Commission will consider the (continued) reimbursement of dexketoprofen with tramadol hydrochloride (Skudexum), empagliflozin (Jardiance), plasma ...

Read more →

EMA publishes EPAR for albutrepenonacog alfa (Idelvion)

31 May 2016 - The EMA has published an EPAR for albutrepenonacog alfa (Idelvion). ...

Read more →

FDA approval of Afstyla (rFVIII-single chain)

26 May 2016 - CSL today announced that the US FDA has approved Afstyla [anti-haemophilic factor (recombinant), single chain], CSL Behring’s ...

Read more →

EMA publishes EPAR for eftrenonacog alfa (Alprolix)

25 May 2016 - The EMA has published an EPAR for eftrenonacog alfa (Alprolix). ...

Read more →